Drug intelligence / Profile preview

5-fluorouracil + bleomycin + cisplatin + methotrexate + vinblastine

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous, Injection, Infusion

Overview

A combination chemotherapy regimen consisting of five anticancer drugs: 5-fluorouracil (5-FU), bleomycin, cisplatin, methotrexate, and vinblastine. Each component has a different mechanism of action: 5-FU is an antimetabolite that interferes with DNA synthesis, bleomycin causes DNA strand breaks, cisplatin forms DNA crosslinks, methotrexate inhibits folate metabolism, and vinblastine disrupts microtubule formation during cell division. This multi-agent approach targets cancer cells through different pathways to potentially enhance efficacy.

Targets

DHFR (Dihydrofolate reductase)DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on 5-fluorouracil + bleomycin + cisplatin + methotrexate + vinblastine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-fluorouracil + bleomycin + cisplatin + methotrexate + vinblastine.

Explore the full profile